Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7. doi: 10.1097/QAI.0b013e318276cda9.

PMID:
23075918
2.

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, Piscitelli S.

Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7. doi: 10.1128/AAC.01235-13.

3.

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.

Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, Wajima T, Savina P, Peppercorn A, Castellino S, Wagner D, Hosking L, Mosteller M, Rubio JP, Piscitelli SC.

Eur J Clin Pharmacol. 2014 Oct;70(10):1173-9. doi: 10.1007/s00228-014-1732-8.

4.

Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.

Brainard DM, Kassahun K, Wenning LA, Petry AS, Liu C, Lunceford J, Hariparsad N, Eisenhandler R, Norcross A, DeNoia EP, Stone JA, Wagner JA, Iwamoto M.

J Clin Pharmacol. 2011 Jun;51(6):943-50. doi: 10.1177/0091270010375959.

PMID:
20852006
5.

Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.

Song I, Mark S, Chen S, Savina P, Wajima T, Peppercorn A, Bala U, Geoffroy P, Piscitelli S.

Drug Alcohol Depend. 2013 Dec 1;133(2):781-4. doi: 10.1016/j.drugalcdep.2013.08.009.

6.

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC.

Antimicrob Agents Chemother. 2010 Jan;54(1):254-8. doi: 10.1128/AAC.00842-09.

7.

Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.

Song IH, Borland J, Chen S, Savina P, Peppercorn AF, Piscitelli S.

Antimicrob Agents Chemother. 2013 Sep;57(9):4394-7. doi: 10.1128/AAC.00728-13.

8.

Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.

Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC.

Antimicrob Agents Chemother. 2014 Nov;58(11):6696-700. doi: 10.1128/AAC.03282-14.

9.

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM.

J Antimicrob Chemother. 2014 Mar;69(3):728-34. doi: 10.1093/jac/dkt421.

10.

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.

Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J.

AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9.

PMID:
21716073
11.

Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.

Shah BM, Schafer JJ, Desimone JA Jr.

Pharmacotherapy. 2014 May;34(5):506-20. doi: 10.1002/phar.1386. Review. Erratum in: Pharmacotherapy. 2014 Jun;34(6):667.

PMID:
24347095
12.

Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.

Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC.

Pharmacotherapy. 2012 Apr;32(4):333-9. doi: 10.1002/j.1875-9114.2012.01033.x.

PMID:
22422361
13.

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Song I, Borland J, Min S, Lou Y, Chen S, Patel P, Wajima T, Piscitelli SC.

Antimicrob Agents Chemother. 2011 Jul;55(7):3517-21. doi: 10.1128/AAC.00073-11.

14.

[Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].

Wajima T, Koshiba T, Ohno K, Nishimura Y, Kobayashi H, Yoshida N, Nagashima M, Fujiwara T.

Jpn J Antibiot. 2013 Feb;66(1):1-7. Japanese.

PMID:
23777012
15.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
16.

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Apr;59(4):690-7.

17.

Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.

Ford SL, Chen YC, Lou Y, Borland J, Min SS, Yuen GJ, Shelton MJ.

Antimicrob Agents Chemother. 2008 Feb;52(2):534-8.

18.

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.

Weller S, Borland J, Chen S, Johnson M, Savina P, Wynne B, Wajima T, Peppercorn AF, Piscitelli SC.

Eur J Clin Pharmacol. 2014 Jan;70(1):29-35. doi: 10.1007/s00228-013-1590-9.

19.

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, Arikan D, Farajallah A, Bertz R.

J Antimicrob Chemother. 2011 Sep;66(9):2075-82. doi: 10.1093/jac/dkr266.

20.

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.

Ross LL, Song IH, Arya N, Choukour M, Zong J, Huang SP, Eley T, Wynne B, Buchanan AM.

BMC Infect Dis. 2016 Jul 22;16:347. doi: 10.1186/s12879-016-1629-5.

Items per page

Supplemental Content

Support Center